Smith & Nephew confirms interest in Biomet
This article was originally published in Clinica
Orthopaedic company Smith & Nephew confirmed today that it has had preliminary talks with US counterpart Biomet regarding a strategic acquisition. A brief statement issued by the London, UK-based company said that no agreement had been reached. Speculation on a merger of the two companies, to form a combined unit with hip sales of $703m and knee sales of $997m, has been building since the US firm and its CEO Dane Miller parted company this spring.
You may also be interested in...
The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.